- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: SLC5A2
Gene name: solute carrier family 5 (sodium/glucose cotransporter), member 2
HGNC ID: 11037
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | INS | 1 hits |
| 2 | PLCG1 | 1 hits |
| 3 | SLC2A1 | 1 hits |
| 4 | SLC5A1 | 1 hits |
| 5 | SLC9A3 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 17050778 | By examining a Chinese hamster ovary-K1 cell line stably expressing either human SGLT2 or human high-affinity sodium glucose cotransporter (SGLT1), we found sergliflozin-A (active form) to be a highly selective and potent inhibitor of human SGLT2. |
| 2 | 19232040 | In animal models of DM, pharmaceutical inhibition of SGLT2 reduces hyperglycaemia, and may improve insulin resistance. |
| 3 | 19852718 | This capacity can be modulated by SGLT2 inhibitors thereby providing a unique insulin independent method of treatment of diabetes. |
| 4 | 19943222 | Dapagliflozin (BMS-512148), a specific inhibitor of the sodium-glucose cotransporter SGLT2, is under development by AstraZeneca plc and Bristol-Myers Squibb Co for the potential oral treatment of type 2 diabetes mellitus (T2DM); a fixed-dose combination of dapagliflozin and metformin is also being developed by the companies for the potential treatment of diabetes mellitus. |
| 5 | 21105857 | Dapagliflozin, a selective inhibitor of sodium glucose transporter 2 (SGLT2), targets hyperglycemia independently of insulin, via decreasing renal glucose reabsorption. |
| 6 | 20980548 | Phlorizin exhibited higher affinity with hSGLT2 (K(i) 11 vs. 140 nM) and a lower Off-rate (0.03 vs. 0.2 s?¹) compared with hSGLT1. |
| 7 | 21140140 | Conversely, the chronic effect of high glucose (25 mM) increased the pH(i) recovery rate (~40%, P < 0.05), without changes in the total levels of NHE1, NHE3, or SGLT1 expression, but increasing the total cellular (~50%, P < 0.05) and the plasma membrane (~100%, P < 0.01) content of SGLT2. |
| 8 | 21358696 | GLUT1 and GLUT2 are associated with SGLT1 and SGLT2, respectively. |
| 9 | 21358697 | Consequently, SGLT2 inhibitors reduce plasma glucose insulin independently and improve insulin resistance in diabetes. |
| 10 | 21358698 | Animal studies suggest that reduction of hyperglycemia with SGLT2 inhibitors may also improve insulin sensitivity and preserve ?-cell function. |
| 11 | 21357472 | SGLT2 knockout mice were protected from HFD-induced hyperglycemia and glucose intolerance and had reduced plasma insulin concentrations compared with controls. |
| 12 | 21357472 | On the db/db background, SGLT2 deletion prevented fasting hyperglycemia, and plasma insulin levels were also dramatically improved. |
| 13 | 21816980 | Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin and may cause fewer of these adverse effects. |